TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31173898
Drug: Decidua stromal
Normalized name: Larix decidua resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decidua stromal cells (DSCs) infused at a median dose of 1.2 (range, 0.9 to 2.9) × 10^6 cells/kg body weight, median of 2 doses given 1 week apart.
Study: 24517061
Drug: Warming Shen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming Shen, enhancing Yang, invigorating qi, and nourishing blood method (WSEYIQNBM) combined artificial cycle therapy
Study: 24517061
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine artificial cycle therapy
Study: 18064333
Drug: G-CSF-mobilized peripheral
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF-mobilized peripheral blood mononuclear cells (M-PBMNC)
Study: 7917743
Drug: Sevoflurane anaesthesia
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane anaesthesia (mean dose 10.6 MAC-h)
Study: 7917743
Drug: Isoflurane anaesthesia
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane anaesthesia (mean dose 8.5 MAC-h)
Study: 17443125
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg nicotine via nasal spray
Study: 17443125
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine via nasal spray
Study: 17443125
Drug: Nicotine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (any dose)
Study: 17274039
Drug: Cabergoline (CAB)
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline (CAB) 2 or 3 mg daily for 30 weeks
Study: 17274039
Drug: Levodopa 200
Normalized name: levodopa 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 200 or 300 mg daily for 30 weeks
Study: 15492340
Drug: Nurse care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse care management (structured telephone surveillance and treatment for heart failure, coordination with primary care physicians)
Study: 8160609
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet and daily physical exercise
Study: 3042053
Drug: CMF +
Normalized name: Cyclophosphamide, Methotrexate, and Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF + tamoxifen (30 mg per day during 2 years)
Study: 3042053
Drug: CMF (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (chemotherapy alone)
Study: 27124254
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care control treatment (including brief peer coaching and brief nurse counseling)
Study: 24408892
Drug: PEERS(®) treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEERS(®) treatment group (TG)
Study: 17403126
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and twice daily biphasic 30/70 human insulin mixture (n = 27)
Study: 17403126
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and bedtime NPH insulin (n = 26)
Study: 17403126
Drug: Metformin, bedtime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, bedtime NPH insulin and mealtime repaglinide (n = 25)
Study: 15871642
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg intravenously (n=37)
Study: 15871642
Drug: prochlorperazine 10
Normalized name: prochlorperazine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: prochlorperazine 10 mg intramuscularly (n=41)
Study: 12851985
Drug: Anti-TNF-alpha immunobiologics
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF-alpha immunobiologics (e.g. etanercept, infliximab)
Study: 12851985
Drug: Apoptosis-inducing treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apoptosis-inducing treatments
Study: 26272720
Drug: Ephedrine 10
Normalized name: pseudoephedrine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 10 mg iv at the time of CSE
Study: 14612479
Drug: Antidepressant medications
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medications and/or 6 to 8 sessions of psychotherapy (Problem‐Solving Treatment in Primary Care)
Study: 11177604
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of isolated disseminated tumor cells in bone marrow (IDTBM) using monoclonal antibody A 45‐B/B3
Study: 1431257
Drug: M15 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: M15 (15 mg/kg)
Study: 1431257
Drug: M25 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: M25 (25 mg/kg)
Study: 3881630
Drug: Intratumoral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral immunotherapy with Corynebacterium parvum followed 2 weeks later by surgery and postoperative C parvum for 2 years
Study: 22816878
Drug: Budesonide/formoterol maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART™, Turbuhaler®) 160/4.5 μg twice daily plus as needed
Study: 22816878
Drug: Conventional fixed-dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fixed-dose treatment (ICS/LABA plus SABA or formoterol)
Study: 10836651
Drug: Daclizumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (1 mg/kg for five doses given every 2 weeks)
Study: 10836651
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (mycophenolate mofetil, prednisone, and a calcineurin inhibitor)
Study: 6392050
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg molsidomine sustained-release
Study: 31304887
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual group
Study: 29456191
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg azithromycin (low-dose)
Study: 29456191
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg azithromycin (standard-dose)
Study: 29456191
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (20 mg/kg and 30 mg/kg azithromycin)
Study: 16383068
Drug: 50 mg/100
Normalized name: Janumet 50 mg/1000 mg Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/100 ml alcohol
Study: 16383068
Drug: 80 mg/100
Normalized name: gentamicin 80 mg/100 mL-0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/100 ml alcohol
Study: 8737213
Drug: Fat-rich meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-rich meal (600 ml, approximately 4000 kJ)
Study: 8737213
Drug: Carbohydrate-rich meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-rich meal (600 ml, approximately 4000 kJ)
Study: 8737213
Drug: Balanced meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced meal (600 ml, approximately 4000 kJ)
Study: 8737213
Drug: Water (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (600 ml)
Study: 1412115
Drug: Resistance breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance breathing training using a resistive breathing device (PFLEX) for 10 minutes five times daily with progressively larger resistances.
Study: 3895960
Drug: Single-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose treatment with 500 mg clotrimazole
Study: 3895960
Drug: 6-day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-day treatment with 100 mg clotrimazole
Study: 26372481
Drug: Doravirine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine 25 mg
Study: 26372481
Drug: Doravirine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine 200 mg
Study: 20152065
Drug: Individual CBT
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual CBT treatment
Study: 16288704
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg/d orally for 1 month)
Study: 12126818
Drug: External irradiation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External irradiation combined with immediate androgen suppression (Goserelin 3.6 mg subcutaneously every 4 weeks for 3 years, and Cyproterone acetate 150 mg orally for 1 month starting 1 week before goserelin)
Study: 7487847
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) without explicit exposure instructions
Study: 7487847
Drug: Exposure and
Normalized name: Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure and response prevention treatment without cognitive restructuring procedures
Study: 2154431
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg bd on day 1 and 250 mg once daily on days 2 to 5)
Study: 2154431
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg qid for ten days)
Study: 19240996
Drug: NHT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHT and adjuvant hormonal therapy (HT)
Study: 11172836
Drug: Progesterone 600
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone 600 mg/d for 3 weeks after a positive hCG result (Control)
Study: 3202502
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline (A)
Study: 28325148
Drug: M2000 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2000 (500 mg twice daily for 12 weeks)
Study: 28325148
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no M2000 treatment)
Study: 26122282
Drug: TDEE(DLW) (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDEE(DLW) (total daily energy expenditure assessed by doubly labeled water)
Study: 18828814
Drug: Non-submerged implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-submerged implants (ITI)
Study: 18828814
Drug: Submerged implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submerged implants (3i)
Study: 16573704
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 microg once daily via Turbuhaler
Study: 16573704
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily via Turbuhaler
Study: 6396969
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg piridoxilate
Study: 6396969
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg piridoxilate (with traffic noise)
Study: 31985066
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + adjunct probiotic therapy (PT) in non-chewers (group 4)
Study: 31985066
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + adjunct probiotic therapy (PT) in shamma users (group 2)
Study: 22399084
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control group (not specified dosage)
Study: 12514150
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg x kg(‐1) tramadol
Study: 12514150
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg x kg(‐1) tramadol
Study: 12514150
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg x kg(‐1) tramadol
Study: 12514150
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg x kg(‐1) tramadol
Study: 8544795
Drug: Regimen DD-RT
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen DD-RT (Vincristine + Actinomycin D + Cyclophosphamide + Whole Lung Radiation Therapy)
Study: 8544795
Drug: Regimen J
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen J (Vincristine + Actinomycin D + Doxorubicin + Whole Lung Radiation Therapy)
Study: 1830551
Drug: Quinapril (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10, 20, or 40 mg day‐1)
Study: 28102978
Drug: Antipsychotic-naive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic-naive patients
Study: 26138109
Drug: Ventral onlay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventral onlay buccal mucosal graft urethroplasty
Study: 9403542
Drug: A‐CVC (antibiotic-
Approvals — FDA: no, EMA: no, PMDA: no
Description: A‐CVC (antibiotic- and antiseptic-coated central venous catheter)
Study: 8218755
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg cisapride b.d.
Study: 31674134
Drug: 0.5-mg intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-mg intravitreal ranibizumab injection
Study: 31674134
Drug: Subconjunctival saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival saline injection (placebo)
Study: 27965209
Drug: Chlorthalidone/amiloride combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone/amiloride combination pill
Study: 16870915
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical management and once-weekly medication dispensing
Study: 16870915
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical management and thrice-weekly medication dispensing
Study: 16870915
Drug: Enhanced medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced medical management and thrice-weekly medication dispensing
Study: 14566214
Drug: Transdermal buspirone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal buspirone patches
Study: 8769938
Drug: GTPN (TPN
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTPN (TPN containing 0.23 g glutamine/kg.day)
Study: 1430300
Drug: diltiazem SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem SR 120 mg
Study: 1430300
Drug: diltiazem SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem SR 240 mg
Study: 1430300
Drug: diltiazem SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem SR 360 mg
Study: 1430300
Drug: diltiazem SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem SR 480 mg
Study: 3950055
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg triazolam tablet in the morning (7 AM)
Study: 3950055
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg triazolam tablet in the evening (10 PM)
Study: 30698839
Drug: Prazosin (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (16 mg)
Study: 19912243
Drug: MMI 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMI 30 mg
Study: 19912243
Drug: MMI 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMI 30 mg + KI
Study: 19912243
Drug: MMI 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMI 15 mg
Study: 19912243
Drug: MMI 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMI 15 mg + KI
Study: 17879223
Drug: email bulimia
Approvals — FDA: no, EMA: no, PMDA: no
Description: email bulimia therapy (eBT)
Study: 17012875
Drug: rDEN1Delta30 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rDEN1Delta30 vaccine (10^3 pfu)
Study: 14616413
Drug: Voriconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (200 mg twice daily)
Study: 8741449
Drug: Infusion cardioplegia
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion cardioplegia with recirculation type circuit
Study: 31912285
Drug: Epiduroscopy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epiduroscopy with mechanical lysis of adhesions and medication (methylprednisolone and hyaluronidase)
Study: 28883722
Drug: Aclidinium/formoterol (AB/FF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium/formoterol (AB/FF) 400/12 μg twice daily
Study: 23881929
Drug: Pazopanib (VEGF-targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (VEGF-targeted agent)
Study: 21241468
Drug: Topical ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Topical ranibizumab (Lucentis®) eye drops (2 mg/ml) four times daily for 1 month
Study: 17163260
Drug: Lornoxicam 24
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 24 mg on day 1 followed by 8 mg twice daily for 5 days
Study: 17163260
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium 150 mg on day 1 followed by 50 mg twice daily for 5 days
Study: 12574810
Drug: Calculated-dose strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated-dose strategy (based on regression formula)
Study: 12574810
Drug: Standard-dose strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose strategy (fixed at 5 mg)
Study: 9109105
Drug: Somatostatin (SRIF-14)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SRIF-14) 50 micrograms administered every hour between 2200 and 0100 hours
Study: 3935298
Drug: Incremental doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental doses of nalbuphine administered approximately four hours after cardiopulmonary bypass
Study: 3935298
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered approximately four hours after cardiopulmonary bypass
Study: 29441995
Drug: S‐1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐1 plus oxaliplatin (SOX) as perioperative chemotherapy (group A, 50 patients)
Study: 29441995
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (group B, 52 patients)
Study: 23164226
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei Shirota 3 times daily for 12 weeks
Study: 23164226
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with standard medical therapy
Study: 12744878
Drug: PFP-3 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFP-3 vaccine
Study: 10586395
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg once daily for 9 days
Study: 12630984
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 9 days
Study: 8738947
Drug: Adequate antibiotic
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate antibiotic therapy
Study: 1662033
Drug: Sinorphan 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinorphan 10 mg
Study: 1662033
Drug: Sinorphan 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinorphan 20 mg
Study: 1662033
Drug: Sinorphan 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinorphan 40 mg
Study: 1662033
Drug: Sinorphan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinorphan (all doses)
Study: 31617335
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg body weight) administered at 11 a.m. or 6 p.m. for 24 weeks
Study: 31617335
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group) administered at 11 a.m. or 6 p.m. for 24 weeks
Study: 29657029
Drug: Pharmacologic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacologic administration of FGF21
Study: 26891181
Drug: Topiramate in
Normalized name: Product containing topiramate in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate in rs2832407*CC genotype
Study: 24262513
Drug: Corinthian Raisins
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corinthian Raisins (CR) consumption (36 g/d, replacing snacks with similar energy density twice daily)
Study: 24262513
Drug: Corinthian Raisins
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corinthian Raisins (CR) consumption (36 g/d)
Study: 22101624
Drug: Tezosentan (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan (3 mg/h for 2-3 h)
Study: 16640173
Drug: Latest antihypertensive
Normalized name: testosterone enanthate Injectable Solution [Delatest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latest antihypertensive drugs
Study: 7743798
Drug: Ciprofloxacin dosing
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin dosing regimen compatible with home use: two drops of 0.3% ciprofloxacin every 4 h over a 24‐h period (Group 1)
Study: 7743798
Drug: Ciprofloxacin dosing
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin dosing regimen applied by a trained professional: two drops of Ciloxan every 15 min over a 4‐h period (Group 2)
Study: 7743798
Drug: Ciprofloxacin dosing
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin dosing regimen applied by a trained professional with corneas abraded (Group 3)
Study: 1903409
Drug: Oral nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nitroglycerin (0.6 mg)
Study: 6168124
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg p.o/day for 5 days
Study: 31498919
Drug: RASB discontinuation
Normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: RASB discontinuation
Study: 28659162
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus herbal medicine and health education
Study: 19324953
Drug: Cross-shift decrease
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-shift decrease in PEF of 5 L.min(‐1)